Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report

The effectiveness of the tyrosine kinase inhibitor ALK (TKI) for non-small cell lung cancer has been confirmed. However, resistance to ALK-TKIs seems inevitable. Mutations in the ALK kinase domain have been reported as an important mechanism of acquired resistance to ALK therapy. However, patients w...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Jiuzhou Zhao, Xiang Li, Ruizhe Fan, Yaping Qin, Zhizhong Wang, Bo Wang, Shaomei Li, Jianfeng Fan, Xinxin Wu, Hongxia Liu, Yuping Guan, Yinfeng Liang, Xiao Zhang, Yongjun Guo
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	Frontiers Media S.A. 2022-11-01
श्रृंखला:	Frontiers in Pharmacology
विषय:	non-small cell lung cancer (NSCLC) next generation sequencing (NGS) EML4-ALK F1174L S1189C de novo mutation
ऑनलाइन पहुंच:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1060460/full
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!